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Hermann Brenner6 • Ben Schöttker6 • Tom Wilsgaard7 • Galatios Siganos7 • Kari Kuulasmaa8 •
Paolo Boffetta9,10 • Antonia Trichopoulou10,11 • Frank Kee1
Received: 21 July 2015 / Accepted: 13 December 2015 / Published online: 18 January 2016
 The Author(s) 2016. This article is published with open access at Springerlink.com
Abstract Seldom have studies taken account of changes
in lifestyle habits in the elderly, or investigated their impact
on disease-free life expectancy (LE) and LE with cardio-
vascular disease (CVD). Using data on subjects aged
50? years from three European cohorts (RCPH, ESTHER
and Tromsø), we used multi-state Markov models to cal-
culate the independent and joint effects of smoking,
physical activity, obesity and alcohol consumption on LE
with and without CVD. Men and women aged 50 years
who have a favourable lifestyle (overweight but not obese,
light/moderate drinker, non-smoker and participates in
vigorous physical activity) lived between 7.4 (in Tromsø
men) and 15.7 (in ESTHER women) years longer than
those with an unfavourable lifestyle (overweight but not
obese, light/moderate drinker, smoker and does not par-
ticipate in physical activity). The greater part of the extra
life years was in terms of ‘‘disease-free’’ years, though a
healthy lifestyle was also associated with extra years lived
after a CVD event. There are sizeable benefits to LE
without CVD and also for survival after CVD onset when
people favour a lifestyle characterized by salutary beha-
viours. Remaining a non-smoker yielded the greatest extra
years in overall LE, when compared to the effects of rou-
tinely taking physical activity, being overweight but not
obese, and drinking in moderation. The majority of the
overall LE benefit is in disease free years. Therefore, it is
important for policy makers and the public to know that
prevention through maintaining a favourable lifestyle is
‘‘never too late’’.
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Introduction
The World Health Organization estimates that 17.3 million
people died from cardiovascular diseases (CVD) in 2008,
representing 30 % of all deaths [1]. Of these deaths, 7.3
million resulted from coronary heart disease (CHD) and 6.2
million from stroke [1]. By 2030, almost 23.6 million
people will die from CVD, mainly from CHD and stroke,
and these are projected to remain the single leading causes
of death [2].
Across the European region there are significant varia-
tions in total life expectancy (LEtot) and in the proportion
of life expectancy (LE) lived without significant self-re-
ported disease or disability [3]. As our LEtot increases,
whether or not the number of years lived with morbidity in
old age will be compressed [4] is a subject of some debate.
Some risk factors in older age may affect incidence and
mortality in divergent ways. Obesity for example increases
incidence risk but apparently has either no effect or may be
protective among those who have experienced a cardio-
vascular event [5]. While there has been some decline in
the prevalence of smoking, current trends in physical
activity, obesity and alcohol consumption are adverse. Few
studies, however, have investigated the independent and
joint effects of these lifestyle factors on LEtot and LE free
of CVD [6]. Previous studies suggest that not smoking [7],
moderate/high levels of physical activity [8], and normal
weight [9] each are associated with a longer LE free of
CVD and LEtot, but to a different extent. Several studies
also show a protective effect of light/moderate and regular
alcohol consumption on total mortality and CVD mortality
[10–12]. The effects on the number of years lived with
CVD also appeared to vary between these behaviours [7–
9].
However, it remains unclear to what extent these results
reflect real differences in the risk factors’ effects, and even
those studies that have analysed all three behaviours have
not examined their joint effects [6]. In addition, previous
studies have seldom accounted for changes in risk factors
and there has been a resurgent interest in such issues given
the possibility that some risk factors may have effects that
are additional and independent from those of a single
baseline assessment [13].
Finally, few studies have looked at CVD outcomes in
countries where lifestyle habits are known to contrast
markedly, which may further help elucidate why outcomes
vary between countries [3].
CHANCES is the Consortium on Health and Ageing:
Network of Cohorts in Europe and the United States and
as such includes a large number of cohorts from all over
Europe and the United States [14]. We use data from
well characterised CHANCES cohorts (ESTHER, Ger-
many; RCPH, Denmark; and Tromsø, Norway) which
have the appropriate repeated measures (of risk factor
covariates) available to analyse how LE with and with-
out CVD is related to the independent and joint effects
of smoking, physical activity, obesity and alcohol con-
sumption, in populations aged 50? years from different
countries.
Methods
Study design and study population
The aim of the CHANCES project is to combine and
integrate prospective cohort studies in order to produce
evidence on ageing-related health characteristics and
determinants [14]. The same analysis script, including the
harmonised endpoints and other variables as outlined
within CHANCES were applied in all cohorts assuring a
high level of comparability. Due to differences in follow up
times, the number of re-contacts, and length of time
between each re-contact, individual cohort analysis was
considered best suited to our purpose rather than attempt-
ing an individual participant meta-analysis. The procedures
followed in all of the cohorts were in accordance with the
ethical standards of the responsible institutional or regional
committee on human research. Written informed consent
was obtained from all participants.
RCPH, Denmark [15]—Participants at baseline
(n = 3785) were excluded if they had prevalent CVD
(n = 90) or were \50 years (n = 1936). The sample size
consisted of 1759 individuals at baseline (1982–1984);
1377 at the first recontact (1987–1988; R1) and 1120 at the
second recontact (1993–1994; R2).
ESTHER, Germany [16]—Participants at baseline
(n = 9949) were excluded if they had prevalent CVD
(n = 1209), or were \50 years (n = 18). The overall
sample size at baseline (2000–2002) consisted of 8482
individuals; 7329 individuals at R2 (2005–2007) and 6242
individuals at R3 (2008–2010).
Tromsø, Norway [17]—For this study, Tromsø surveys
T4 and T5 were included. Participants at T4 baseline
(n = 10,252) were excluded if they had prevalent CVD
(n = 1073). The sample size consisted of 9179 individuals
at baseline (1994–1995) and 5211 individuals at T5 (2001).
All participants were C50 years at baseline.
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Exposures and covariates
At baseline, height and weight was assessed and docu-
mented in all cohorts. Similar procedures were adhered to
at subsequent re-contacts, except ESTHER which collected
self-reported height and weight; those who had a home-
visit at R3 (*45 %) had these anthropometric measure-
ments documented. Age, sex, smoking status (never, for-
mer, current), alcohol intake [abstainer (0 g daily);
light/moderate = men ([0 g and \60 g daily), women
([0 g and \40 g daily); heavy = men (C60 g daily),
women (C40 g daily)], physical activity (any vigorous
activity at least once per week to cause increased breath-
ing/sweating, yes/no), hypertension (based on measured
blood pressure and hypertensive drug treatment use) and
total/HDL cholesterol ratio were available in all cohorts. A
variable based on a combination of self-reported hyper-
tension and hypertensive drug treatment use was employed
as a proxy for R2 in ESTHER as blood pressure was not
measured at this recontact. Prevalent diabetes was also
available, but was documented in ESTHER and self-re-
ported in RCPH and Tromsø. All variables used in the
analyses from different cohorts were harmonised according
to pre-agreed CHANCES data harmonisation rules [18].
Outcomes
All cohorts obtained the exact date of death from an official
death register. Follow-up of fatal and nonfatal CVD [acute
coronary event or stroke (type unspecified)] used similar
techniques, including responses to follow-up question-
naires, hospital discharge registers and general practitioner
or independent endpoint committee confirmation. More
detailed descriptions of the cohorts, exposures, covariates
and outcomes are available online [18].
Statistical methods
A multi-state Markov model was employed [19], being a
useful way of describing a process in which an individual
moves between states in continuous time. Here a non-re-
coverable illness-death model was constructed (see Fig. 1,
with individuals starting free of CVD in state 1 at time t,
and moving to either a nonfatal CVD event in state 2 or
death of any cause at state 3—competing risk), in order to
assess associations between each of the major lifestyle
behaviours (smoking, physical activity, BMI and alcohol
consumption) and LE with and without CVD. Individuals
who suffer a fatal CVD event (or die from any cause) move
directly from state 1 to state 3 without first moving to state
2, while those who have a nonfatal CVD event move from
state 1 to state 2 and then either stay in state 2 or move to
state 3 if they should die from any cause at a later follow-
up point. When using the repeated measures of covariates
in the Markov model, the most recent available value for
each measurement was used in the analysis when an event
occurred.
The parameters of such a three state model were esti-
mated through use of the R msm package [20] with the
instantaneous risk of moving from state i to state j influ-
enced by the characteristics of individuals (either time-
dependent or constant covariates) in a proportional hazards
fashion. LE was calculated following the techniques of the
R ELECT package [21].
A secondary joint analysis was performed, where men
and women were grouped separately into two lifestyle
categories: ‘‘favourable’’ (those who are overweight but not
obese, light/moderate drinkers, and are non-smokers and
participate in vigorous physical activity); versus ‘‘un-
favourable’’ (those who are overweight but not obese,
light/moderate drinkers, and are smokers and do not par-
ticipate in vigorous physical activity) [Because of small
cell counts within joint categories, and the consequent non-
convergence of the MSM models, it was not possible to
create ‘‘lifestyle’’ stereotypes in which all four risk factors
varied.] The same statistical techniques as outlined above
were used for this joint analysis.
A detailed description of the statistical methods
employed can be found in the Supplementary Material,
Online Resource.
Results
Table 1 shows the baseline characteristics of all three
cohorts. With the exception of BMI, subjects in the more
recent ESTHER cohort have somewhat ‘‘healthier’’ life-
styles than in the other cohorts with lower smoking rates
and higher rates of physical activity. Although ESTHER is
the second largest cohort, it only contributes approximately
33 % of the 233,406 total person years of follow-up,
because it is the most recently established cohort. The
Supplementary Material (Online Resource) provides the
Fig. 1 Multistate Markov model used with individuals being in one
of three possible states at time t: Xt = 1 (free of CVD), Xt = 2
(nonfatal CVD) or Xt = 3 (all-cause death)
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Hazard Ratios for each major lifestyle risk factor
(Tables S1–S3). These are used, as described in the
detailed statistical methods (Online Resource), to derive
the impact of the lifestyle related risk factors, accounting
for other covariates, on LEtot, LE free of CVD and LE with
CVD (after first event).
The effects on life expectancies of each risk factor are
illustrated in Tables 2, 3 and 4 for each sex separately at
50 years old with levels of the other covariates set to the
mean values in the cohort. Across all three cohorts,
remaining a non-smoker yielded the largest positive dif-
ferences in LEtot, when compared to the effects of routinely
taking vigorous physical activity, being overweight but not
obese, and drinking in moderation. For example, among
RCPH men there were: 5.8 more LEtot years from
remaining a non-smoker compared to 3.1 more LEtot years
from routinely taking vigorous physical activity, 0.9 more
LEtot years from being overweight but not obese, and 2.7
more LEtot years from drinking in moderation compared to
heavy drinkers. Among ESTHER women: 9.2 more LEtot
years from remaining a non-smoker compared to 6.9 more
LEtot years from routinely taking vigorous physical activ-
ity, 3.9 more LEtot years from being overweight but not
obese, and 6.0 more LEtot years from drinking in moder-
ation compared to heavy drinkers. The largest proportion of
LEtot in these three CHANCES cohorts is attributed to
disease free years. For example, in Tromsø men: never
smokers have 23.9 LE years free of CVD and 3.8 LE years
Table 1 Characteristics of the CHANCES cohorts
Baseline characteristic Cohort
RCPH (Denmark) ESTHER (Germany) Tromsø (Norway)
Baseline year 1982–1984 2000–2002 1994–1995
Baseline total N 1759 8482 9179
Sex, males (%) 51.2 43.7 45.0
Age, mean (SD) 54.9 (5.0) 61.8 (6.6) 62.4 (9.5)
Systolic blood pressure (mmHg), mean (SD) 130.2 (18.2) 139.7 (19.5) 146.5 (23.3)
Diastolic blood pressure (mmHg), mean (SD) 80.1 (10.6) 83.8 (10.3) 84.0 (13.1)
Hypertension, yes (%) 32.3 56.4 58.9
Total cholesterol (mmol/L), mean (SD) 6.2 (1.2) 5.7 (1.3) 6.7 (1.3)
HDL-cholesterol (mmol/L), mean (SD) 1.5 (0.5) 1.4 (0.4) 1.6 (0.4)
Total/HDL cholesterol ratio, mean (SD) 4.4 (1.6) 4.5 (1.6) 4.6 (1.5)
Vigorous physical activity, yes (%) 18.1 43.8 33.6
Prevalent diabetesa, yes (%) 3.0 15.9 2.4
Body mass index (%)
Underweight,\18.5 1.5 0.4 1.4
Normal, C18.5 and\25 47.8 27.8 41.0
Overweight, C25 and\30 38.0 47.1 42.8
Obese, C30 12.7 24.5 14.7
Alcoholb (%)
Abstainer 17.3 28.4 25.5
Light/moderate 78.9 62.6 51.3
Heavy 3.8 0.3 0.04
Smoking (%)
Never daily smoker 39.7 49.8 34.6
Former daily smoker 16.5 31.3 33.8
Current daily smoker 42.6 16.5 31.5
Mean follow-up, range (years) 21.0, 0.1–27.2 9.1, 0.06–10.5 13.0, 0.1–16.3
Total person-years 36,931.1 77,386.1 119,089.1
Original baseline data (no imputation); excludes history of CVD and\50 years old at baseline; % do not always round to 100 % due to missing
values before imputation
a Documented (ESTHER) or self-reported (RCPH & Tromsø)
b Light/moderate = men ([0 g and\60 g daily), women ([0 g and\40 g daily); Heavy = men (C60 g daily), women (C40 g daily)
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with CVD. RCPH women who routinely take vigorous
physical activity have 26.4 LE years free of CVD and 3.0
LE years with CVD.
Compared to the other cohorts, ESTHER had the largest
positive differences in LE from participating in vigorous
physical activity, even among those active after a first
event. For example, ESTHER men: 6.8 more LEtot years
and 4.3 more LE years free of CVD, and 2.4 more LE years
with CVD; RCPH men: 3.1 more LEtot years; 2.5 more LE
years free of CVD, and 0.6 more LE years with CVD.
Each of the cohorts displayed a survival advantage, in
terms of LEtot among those in the overweight category. For
example, ESTHER men and women respectively; 3.9 more
LEtot years from being overweight and 1.0 and 1.2 more
LEtot years from being obese. Also, the obese in the
Tromsø cohort had an apparent longevity advantage after
an incident CVD event (Table 4); in men and women
respectively, the obese had 4.8 and 3.6 LE years compared
to 4.5 and 3.4 LE years with CVD for the overweight
participants. More than 1 year lived free of CVD in the
overweight, compared to those with normal BMI (both
sexes) was observed in all cohorts except Tromsø.
RCPH and ESTHER exhibited a survival advantage
from light/moderate alcohol intake, though the absolute
magnitude of the LEtot benefit varies between *3 and
*6 years when comparing heavy with light/moderate
drinkers and between *1 and *3 years when light/mod-
erate drinkers are compared to abstainers. A similar sur-
vival advantage was observed in Tromsø, but was
relatively negligible when comparing light/moderate drin-
kers and abstainers (*0.5 for both sexes), and still evident
when comparing light/moderate drinkers and heavy drin-
kers (1.4 and 0.9 more LEtot years for men and women,
respectively).
The similarities and contrasts across cohorts are illus-
trated in Figures S1a-f (Online Resource).
A joint analysis grouped men and women into two
lifestyle categories: ‘‘favourable’’ versus ‘‘unfavourable’’
and the results are shown in Table 5. The difference in
LEtot between these two groups ranges from *7 years
among men in Tromsø to *16 years among women in the
ESTHER study. While most of the differences in LE are in
terms of life-years free of CVD, those with favourable
lifestyles after a CVD event tended to live between 1 and
2 years longer in the Danish and German cohorts, which
was not seen in the Norwegian cohort.
Discussion
The reduction in mortality rates from CVD, over more than
three decades in some western European countries, is a
public health success story. Though the contribution to thisT
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decline by changes in CVD incidence secondary to changes
in risk factor prevalence is somewhat contested, consensus
has emerged that the majority of the decline has been due
to changes in lifestyle related risk factors, rather than
treatment [22, 23].
Our findings bear similarities to some previous studies
[6], but by accounting for repeated measures of lifestyle
factors within our multi-state transition model, we have
methodologically extended previous work. Analyses that
use only a single baseline assessment of lifestyle cannot
account for possible changes in these, which may lead to a
biased estimation of risk. These previous studies [6–9]
have focused on subjects recruited at younger ages than in
this analysis of CHANCES cohorts and it is important for
policy makers and the public to know that prevention is
still possible later in life.
Overall, some consistent patterns are discernible in the
impact of lifestyle risk factors on LEtot and LE free of CVD
across the three cohorts that were studied. For 50 year olds,
across all three cohorts, remaining a non-smoker yielded
the largest positive differences in LEtot, when compared to
the effects of routinely taking vigorous physical activity,
being overweight but not obese, and drinking in modera-
tion. This is consistent with other findings [6, 24, 25], but it
should be noted that by far the largest proportion of the LE
in these three CHANCES cohorts was attributed to disease
free years emphasising the much greater population divi-
dend from maintaining a favourable lifestyle.
It is at first surprising that at least in the ESTHER and
Tromsø cohorts, smokers had an apparent (though small)
longevity advantage after an incident CVD event. It should
be noted that the confidence intervals are wide and this
apparent difference may be spurious. It is claimed that such
seemingly perverse findings may represent a form of sur-
vivorship bias [26] whereby death has harvested the
‘‘weakest’’ smokers who succumb to a first event, leaving
those who survived as an unrepresentative but ‘‘hardy’’
subsample. Another interesting finding from this study was
the apparent large differences in LEtot between the cohorts,
with ESTHER having the highest overall LE at age 50 years
for both males and females, regardless of risk factor. The
reason for this may be that the ESTHER cohort have some-
what ‘‘healthier’’ lifestyles than the other cohorts as outlined
previously. Alternatively, the direction of the differences are
consistent with the fact that RCPH baseline was 20 years
earlier and Tromsø was 10 years earlier than ESTHER; there
has been substantial increases in life expectancy over time
due to medical advances and lifestyle changes, such as a
sharp decline in the prevalence of smoking in recent decades.
While the majority of the life years from participating in
vigorous physical activity arise in years of life lived free of
CVD, there is still a material advantage observed among
those active after a first event, which is consistent with theT
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benefits reported for various cardiac rehabilitation pro-
grammes that emphasize graded physical activity [27].
There are substantial differences in the absolute magnitude
of the overall survival advantage from vigorous physical
activity across cohorts and a possible interpretation is
likely to lie in the nature and methods of sample recruit-
ment and measurement of physical activity, where it is
apparent that far more people in ESTHER (than in for
example RCPH) state that they regularly participated in
regular vigorous physical activity. Of course in order to
properly quantify the health benefits of regular physical
activity we would require accelerometry, which was not
available when, for example, the RCPH study commenced.
Each of our cohorts showed a survival advantage, in
terms of LEtot, among those in the overweight category.
More than 1 year lived free of CVD in the overweight,
compared to those with normal BMI (both sexes) was
observed in all cohorts except Tromsø. The smaller number
of obese subjects and wider confidence intervals signifies
that their overall LE is difficult to distinguish from those of
normal weight in our cohorts, although the underweight
subjects fare significantly worse and this can commonly be
explained by subclinical or occult diseases, smoking, sar-
copenia, and frailty [28–30]. As it is difficult to fully
account for all such conditions, further research on this
group of people is warranted, particularly in the older
population. The years of life lived after a CVD event are
likewise higher in the overweight subjects than among the
normal weight subjects at least in the ESTHER and Tromsø
cohorts, by around one and 2 years, respectively, though
this trend is not apparent in the RCPH data. This greater
survival after an event among the overweight has been
observed by others [9]. Paradoxically, the obese in Tromsø
displayed more years lived after a CVD event, greater than
1 year for both sexes, compared to the normal and over-
weight categories. This could potentially reflect the
hypothesised ‘‘obesity paradox’’, but the existence of such
has been disputed [31]. We cannot establish the extent to
which the association between obesity and number of years
lived free of and with CVD is causal. Several hypotheses
have been put forward to explain such findings. Heavier
individuals may present earlier for medical treatment for
obesity related conditions including cholesterol reduction,
diabetes and hypertension [32]. Alternatively, there may be
‘‘cardioprotective’’ metabolic effects of increased body fat
in times of chronic illness [33]. Small increases in BMI
(e.g. normal ? overweight category) can be due to an
increased lean mass which may be associated with
improved metabolic profiles and better prognosis in rela-
tion to chronic illness and mortality [32].
All the cohorts’ accord well in pointing to a survival
advantage from light/moderate alcohol intake, though the
absolute magnitude of the LEtot benefit varies as outlined inT
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the results. A majority of the benefit from moderate intake
appears to arise from a reduced incidence of events and a
greater event free survival, but there still appears to be a
survival benefit after disease onset. While the reported
J-shaped curve between intake and CVD mortality has
been thought to arise in part from subsamples of non-
drinkers who gave up because of some ill health effects,
this would not be a powerful explanation for our own
findings, since we accommodated repeated measures of
behaviours in our analysis. On the other hand, we
acknowledge that we have only crudely categorised
‘‘heavy’’ drinkers and have not been able, with this data, to
tease out any distinct effects of binge drinking [34]. Nor
did our sample size justify a greater number of Markov
states to separate coronary heart disease events from stroke
events, and the effects of heavy drinking are likely to be
stronger on stroke incidence and mortality [35, 36].
All our cohorts demonstrate the sizeable benefits to LE
without CVD and also for survival after CVD onset, when
people favour a lifestyle characterized by salutary beha-
viours: not smoking, light/moderate drinking, taking reg-
ular exercise, and a modest excess BMI. Those who have a
favourable lifestyle live between *8 and *16 years
longer overall, of which (with the exception of Tromsø)
between *1 and *2 extra years is apparent after an event.
These values accord broadly with those reported by Nus-
selder et al. [6], but the population in the latter Framing-
ham study was younger at baseline (28–62 years) and so an
important message from our results is that the LE benefits
of maintaining a favourable lifestyle applies among older
subjects as well as the young. Some differences in these
estimates from those in other studies might be expected, as
we have derived them by setting other covariates to their
mean value and the distribution of such variables will vary
from population to population.
Some limitations of our study need to be considered.
Although all data were harmonised based on agreed rules
(www.chancesfp7.eu; [14, 18]), the data from the dif-
ferent cohorts are not perfectly comparable, due to dif-
ferences in study design and data collection procedures,
with the potential for residual inconsistencies in variable
definitions, e.g. retrospective standardization of physical
activity data is known to be very difficult, and there
have been major difficulties in standardizing physical
activity questionnaires across countries [18]. Addition-
ally, not all detailed endpoints, including all CVDs were
possible to be coded within all CHANCES cohorts due
to data availability, including non-CVDs. Therefore, we
could not completely take into account all other com-
peting risks within the current analysis. Because of our
desire to incorporate repeated measures of risk factors,
which previous similar studies have not yet attempted,
we did not consider it useful or feasible to conduct an
individual subject meta-analysis, as the intervals between
follow-up examinations in the cohorts were different.
When using the repeated measures of covariates in the
Markov model, the most recent available value for each
measurement was used in the analysis. However, the
repeated measures were not always taken frequently and
in many cases of non-fatal CVD (state 2) the last mea-
surement was taken when the person was in state 1
(recontact dependent with some participants having
measurements taken closer to the event than others).
Such measurements may not wholly reflect the risk
factor levels at state 2 because after a nonfatal CVD
event, a person is going to be under aggressive inter-
vention to alter his/her risk factors, and that person is
usually motivated to change their lifestyle. Nevertheless,
this model is much better and more robust than simply
relying solely on the baseline measurements of the risk
factors. For example, smoking is known to advance
death, so having repeated measures we can take the most
recent available measurement so as to account for
someone who may become an ex-smoker after moving to
state 2 rather than assuming they remain a smoker if we
just used baseline measurements. Furthermore, CHAN-
CES has no data on the acute treatment of the incident
events. While it is accepted that salutary behaviours have
benefits of comparable magnitude to many treatments
[37], treatment effects in this phase of disease may
clearly confound the effects of the lifestyle risk factors.
While Ko et al. propose [38], and demonstrate empiri-
cally, that older patients with shorter LE actually receive
evidence based treatments less frequently than younger
subjects, we have no basis for thinking that acute CVD
treatments after an event are correlated with our exam-
ined risk factors in these cohorts. Insofar as some
treatments might plausibly be offered more frequently to
higher risk patients than lower risk patients (e.g. obese
vs. lean patients receiving more careful monitoring or
treatment with blood pressure lowering agents), the
benefits of lifestyle change might be over-estimated,
though the final direction and significance of confound-
ing by treatment effects (after disease onset) in our study
is unknown. Studies have consistently demonstrated that
abdominal obesity may be a better predictor for mortality
and disease outcomes than overall obesity [39, 40]. This
may be particularly relevant in the elderly due to age-
related changes in body composition, such as a decrease
in muscle mass, increase in fat mass, and loss of height
[41]. Regardless, BMI continues to be widely used in
epidemiological studies and it was universally available
across all cohorts and follow-ups unlike other measures
of adiposity such as waist-to-hip ratio. Although sex-
differences in our analyses were not always apparent, we
chose to present sex-stratified results due to differences
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in the lifestyle risk factors among the individual cohorts,
and also due to a priori understanding that the impact of
various risk factors, such as smoking is different between
men and women [42].
In conclusion, there are sizeable benefits to LE without
CVD and also for survival after CVD onset when people
favour a lifestyle characterized by salutary behaviours.
Remaining a non-smoker yielded the greatest extra years in
overall LE, when compared to the effects of routinely
taking physical activity, being overweight but not obese,
and drinking in moderation. The majority of the overall LE
benefit is in disease free years. Given the higher incidence
of cardiovascular events and mortality in older age, life-
style choices in the older population could probably
achieve even greater absolute risk reductions for adverse
cardiovascular events. Perceptions of LE are associated
with a variety of health-related behaviours [43] and so it is
important that the benefits of maintaining a favourable
lifestyle are known by older subjects. Additionally, having
a means of showing LE with and without disease may be a
useful communication tool for this section of the popula-
tion [44].
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